Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Berlex' Ultravist x-ray/CT imaging agent approved May 10; launch slated for July.

This article was originally published in The Gray Sheet

Executive Summary

BERLEX ULTRAVIST CONTRAST AGENT WILL BE AVAILABLE IN JULY, the company announced May 12. The iodinated, non-ionic contrast agent iopromide for x-ray imaging and computed tomography scanning was approved by FDA on May 10, almost two years after FDA's Medical Imaging Drugs Advisory Committee unanimously recommended approval for eight indications ("The Gray Sheet" May 31, 1993, p. 14).

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel